Oncocyte Company Profile News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncocyte company profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncocyte Company Profile Today - Breaking & Trending Today

OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note published on Friday. The brokerage issued a sell rating on the stock. Several other brokerages have also recently weighed in on OCX. Needham & Company LLC reiterated a buy rating and issued a $4.25 price objective on shares of OncoCyte […] ....

United States , Andrew Arno , Oncocyte Corporation , Needham Company , Securities Exchange Commission , Oncocyte Company Profile , Free Report , Director Andrew Arno , Exchange Commission , Broadwood Partners , Get Free Report , Cyte Corporation , Oncocyte Daily ,

OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com

OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United States , Andrew Arno , Needham Company , Oncocyte Corporation , Securities Exchange Commission , Oncocyte Company Profile , Free Report , Director Andrew Arno , Exchange Commission , Broadwood Partners , Get Free Report , Cyte Corporation , Oncocyte Daily ,

OncoCyte (NASDAQ:OCX) PT Raised to $4.25 at Needham & Company LLC

OncoCyte (NASDAQ:OCX – Get Free Report) had its target price increased by equities researchers at Needham & Company LLC from $3.60 to $4.25 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price target would suggest a potential upside […] ....

United States , Andrew Arno , Oncocyte Company Profile , Needham Company , Oncocyte Corporation , Securities Exchange Commission , Get Free Report , Cyte Trading Down , Director Andrew Arno , Broadwood Partners , Exchange Commission , Cyte Corporation , Oncocyte Daily ,

OncoCyte (NASDAQ:OCX) Given New $4.25 Price Target at Needham & Company LLC

OncoCyte (NASDAQ:OCX – Get Free Report) had its price objective boosted by equities researchers at Needham & Company LLC from $3.60 to $4.25 in a note issued to investors on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price target points to a potential upside of […] ....

United States , Andrew Arno , Oncocyte Corporation , Needham Company , Oncocyte Company Profile , Get Free Report , Broadwood Partners , Director Andrew Arno , Cyte Corporation , Oncocyte Daily , Nasdaq Ocx , Boost Price Target , Needham Company Llc ,

OncoCyte (NASDAQ:OCX) Given New $4.25 Price Target at Needham & Company LLC

OncoCyte (NASDAQ:OCX) Given New $4.25 Price Target at Needham & Company LLC
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United States , Andrew Arno , Needham Company , Oncocyte Corporation , Oncocyte Company Profile , Get Free Report , Broadwood Partners , Director Andrew Arno , Cyte Corporation , Oncocyte Daily ,